Micoral 2%30 gm

Micoral 2% is an imidazole antifungal used to treat a range of superficial fungal infections. Evidence and approved use vary by formulation (topical cream/powder/spray, vaginal cream/suppository, or oral gel).

Established / approved uses

• Dermatophyte (tinea) infections: tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm), topical formulations.
• Cutaneous candidiasis: skin infections caused by Candida species.
• Tinea versicolor: topical formulations of Micoral 2% are used to treat this superficial yeast infection.
• Vulvovaginal candidiasis: vaginal cream/suppository formulations of Micoral 2% are used for vaginal yeast infections.

Formulation-dependent / locally approved use

• Oropharyngeal candidiasis (oral thrush): oral gel formulations of Micoral 2% are used in some markets (including Bangladesh) for local treatment of oral thrush; this formulation is not marketed in all countries.

Your physician or pharmacist will select the specific formulation and duration of Micoral 2% appropriate for your diagnosis.

Each formulation of Miconazole USP contains micronized Miconazole USP (miconazole nitrate) as the active pharmaceutical ingredient, at a strength appropriate to the dosage form (e.g., topical cream/powder 2%, vaginal cream/suppository, or oral gel). Please refer to the specific product label for exact strength and excipients.

Micoral 2% is a synthetic imidazole-derivative antifungal agent used topically, vaginally, or orally (as a local oral gel) for the treatment of superficial fungal and yeast infections. It is active against dermatophytes (such as Trichophyton, Epidermophyton, and Microsporum species) and yeasts (particularly Candida albicans).

Micoral 2% is available in several dosage forms including cream, powder, spray, vaginal cream/suppository, and oral gel, allowing formulation-specific treatment of skin, vaginal, and oral fungal infections.

Micoral 2% belongs to the imidazole class of antifungal agents, a subgroup of azole antifungals used for the topical, vaginal, and local oral treatment of superficial fungal and yeast infections.

Miconazole USP exerts its antifungal effect by inhibiting the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, which blocks the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane.

Depletion of ergosterol and accumulation of toxic sterol intermediates disrupts fungal cell membrane structure and function, leading to increased membrane permeability, leakage of cellular contents, and inhibition of fungal growth (fungistatic effect); at higher concentrations Miconazole USP can be fungicidal against susceptible organisms.

Topical, vaginal, and oral-gel formulations of Miconazole USP act primarily at the local site of application, with minimal to limited systemic absorption depending on the formulation and mucosal surface involved.

Topical: Clean and dry the affected area before applying Micoral 2%. Gently rub in a thin layer. Wash hands after application unless the hands are the area being treated.

Vaginal: Insert the applicator or suppository high into the vagina, preferably at bedtime, using the applicator provided with the product.

Oral gel: Apply Micoral 2% oral gel directly to the affected areas inside the mouth using a clean finger, after food, and try to keep it in contact with the mouth lining for as long as possible before swallowing.

Complete the full recommended course of Micoral 2% even if symptoms improve earlier, to reduce the risk of recurrence. Avoid contact with the eyes.

Topical and vaginal Micoral 2% have minimal systemic absorption, so clinically significant drug interactions are uncommon with these routes, though caution is still advised.

Oral gel formulations of Micoral 2% carry a clinically important interaction risk even though systemic absorption is limited: Micoral 2% (oral gel) can inhibit CYP2C9 and CYP3A4 enzymes, leading to:

• Warfarin and other oral anticoagulants: significantly enhanced anticoagulant effect and increased bleeding risk; concomitant use requires close monitoring of coagulation parameters (e.g., INR) or should be avoided.
• Sulfonylurea antidiabetic agents: increased risk of hypoglycemia.
• Phenytoin and other CYP-metabolized drugs: altered drug levels are possible with oral gel formulations of Micoral 2%.

Tell your physician about all medicines you are taking before starting Micoral 2%, particularly if you are using the oral gel formulation.

Micoral 2% is generally well tolerated, especially with topical and vaginal use. Reported side effects include:

• Local burning, stinging, itching, or irritation at the site of application
• Mild skin redness or contact dermatitis
• Vaginal irritation, itching, or discharge (with vaginal formulations)
• Nausea or an unpleasant taste (with oral gel)
• Rarely, allergic hypersensitivity reactions (see Contraindications)

If severe irritation, rash, or signs of an allergic reaction occur while using Micoral 2%, discontinue use and consult a physician.

Pregnancy: Topical and vaginal Micoral 2% are generally considered low-risk when used as directed, and are commonly used for vulvovaginal candidiasis in pregnancy; however, Micoral 2% should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. The oral gel formulation of Micoral 2% has more limited safety data in pregnancy and should be used only under medical advice.

Lactation: It is not known whether topically or vaginally applied Micoral 2% is excreted in clinically significant amounts in human milk. Use Micoral 2% during breastfeeding only if considered necessary by a physician, avoiding application directly on or near the breast/nipple area.

Always consult a physician before using Micoral 2% during pregnancy or breastfeeding.

• Use Micoral 2% exactly as prescribed or as directed on the product label; do not stop, extend, skip doses, or share this medicine with others without medical advice, and complete the full recommended course even if symptoms improve early.
• For external/vaginal use only unless a formulation is specifically labeled for oral use; avoid contact with the eyes.
• If irritation, burning, or sensitivity worsens or persists, discontinue Micoral 2% and consult a physician.
• Oral gel formulations of Micoral 2% should be used with caution in patients on warfarin or other interacting medicines (see Interactions), and are not recommended for infants under 4 months of age due to a risk of choking.
• If symptoms of infection do not improve within the expected timeframe, or if they recur, consult a physician to confirm the diagnosis.

Topical or vaginal Micoral 2% used as directed is very unlikely to cause systemic overdose due to limited absorption. If a large amount of Micoral 2% is accidentally swallowed, or if oral gel is ingested in excess, mild gastrointestinal upset may occur.

In case of suspected overdose or accidental ingestion of Micoral 2%, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: No dose adjustment is established or generally required for topical, vaginal, or oral gel Micoral 2%, given minimal systemic absorption; use with routine caution.

Hepatic impairment: No specific dose adjustment is established for topical/vaginal Micoral 2%; oral gel should be used with caution in significant hepatic impairment given the potential for enzyme interactions.

Elderly: No specific dose adjustment is required for Micoral 2% in elderly patients using topical or vaginal formulations.

Immunocompromised patients: May require closer follow-up and, in some cases, systemic antifungal therapy rather than Micoral 2% alone if superficial candidiasis does not respond, or if infection is extensive.

Duration of treatment with Micoral 2% depends on the indication and formulation: typically 2-4 weeks for tinea infections of the skin, 1-7 days for vaginal candidiasis (depending on product strength), and about 1-2 weeks for oral thrush with oral gel. Treatment with Micoral 2% should generally be continued for a few days after symptoms resolve, and the full recommended course should always be completed.

Antifungal agent; Imidazole derivative (azole antifungal)

Miconazole USP inhibits the fungal enzyme lanosterol 14-alpha-demethylase (a cytochrome P450-dependent enzyme), blocking conversion of lanosterol to ergosterol. This depletes ergosterol in the fungal cell membrane and causes accumulation of toxic methylated sterol precursors, disrupting membrane integrity and function, which inhibits fungal growth and can be fungicidal at higher local concentrations.

C

Topical Micoral 2% preparations are used in children for tinea and cutaneous candidal infections, generally following the same application principles as in adults, under medical or pharmacist guidance for the appropriate age and formulation.

Oral gel Micoral 2% is not recommended for infants under 4 months of age because of a risk of choking, and should be used in older infants and children only under medical supervision with a small, age-appropriate amount applied to the mouth.

Safety and efficacy of Micoral 2% in neonates and very young infants have not been well established for all formulations; a physician should be consulted before use in this age group.